Drug Interaction Study With a Potential Alzheimer's Disease Compound

Bristol-Myers Squibb (BMS)

Status and phase: Completed; Phase 1

Conditions: Alzheimer Disease

Treatments: Drug: BMS-708163; Drug: BMS-708163 + Cooperstown Cocktail; Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)

Study type: Interventional

Funder types: Industry

Identifiers

NCT00726726

CN156-005

Details and patient eligibility

About

The purpose of this study is to determine whether BMS-708163 will effect the pharmacokinetics of the commonly prescribed medicines midazolam, warfarin, caffeine,omeprazole and dextromethorphan

Enrollment: 22 patients

Sex: Male

Ages: 18 to 45 years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy male subjects
• 18-45 yrs old inclusive

Exclusion criteria

• Women

Trial design

Primary purpose: Treatment

Allocation: Non-Randomized

Interventional model: Single Group Assignment

Masking: None (Open label)

---

22 participants in 3 patient groups

A

Other group

Treatment:

Drug: Interacting drugs - Cooperstown Cocktail (midazolam, warfarin, (+ vitamin K), caffeine, omeprazole and dextromethorphan)

B

Experimental group

Treatment:

Drug: BMS-708163

C

Experimental group

Description:

+ Other

Treatment:

Drug: BMS-708163 + Cooperstown Cocktail